BeyondSpring (BYSI) Common Equity (2015 - 2026)
BeyondSpring (BYSI) posted Common Equity of -$34.5 million for Q1 2026, down 7.23% sequentially from -$32.2 million in Q4 2025, and down 172.26% YoY from $47.7 million in Q1 2025.
BeyondSpring (BYSI) Common Equity (2015 - 2026) Analysis & Trends
BeyondSpring has reported Common Equity for 12 years, with the latest figure at -$34.5 million in Q1 2026.
- Quarterly Common Equity fell 172.26% year-over-year to -$34.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.5 million (down 172.26% YoY) and the FY2025 annual result came in at -$32.2 million, down 125.14% from the prior year.
- Common Equity slipped to -$34.5 million in Q1 2026 per BYSI's latest filing, from -$32.2 million in the prior quarter.
- Over five years, Common Equity peaked at $8.1 million in Q2 2022 and troughed at -$38.5 million in Q2 2024.
- A 5-year average of -$22.9 million and a median of -$26.2 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2025: Common Equity slumped 422.66% in 2023, then soared 66.81% in 2025.
- Over 5 years, Common Equity stood at -$14.1 million in 2022, then tumbled by 150.94% to -$35.3 million in 2023, then jumped by 59.57% to -$14.3 million in 2024, then tumbled by 125.14% to -$32.2 million in 2025, then slipped by 7.23% to -$34.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$34.5 million, -$32.2 million, and -$31.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | -36.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.03 Mn |
| Mar 31, 2026 | -34.49 Mn |
| Dec 31, 2025 | -32.16 Mn |
| Sep 30, 2025 | -31.78 Mn |
| Jun 30, 2025 | -17.55 Mn |
| Mar 31, 2025 | -12.67 Mn |
| Dec 31, 2024 | -14.29 Mn |
| Sep 30, 2024 | -11.02 Mn |
| Jun 30, 2024 | -38.55 Mn |
| Mar 31, 2024 | -38.17 Mn |
| Dec 31, 2023 | -35.34 Mn |
| Jun 30, 2023 | -26.16 Mn |
| Dec 31, 2022 | -14.08 Mn |
| Jun 30, 2022 | 8.11 Mn |
| Dec 31, 2021 | 20.92 Mn |
| Sep 30, 2021 | 38.33 Mn |
| Jun 30, 2021 | 55.31 Mn |
| Mar 31, 2021 | 72.51 Mn |
| Dec 31, 2020 | 86.63 Mn |
| Sep 30, 2020 | 22.92 Mn |